theratechnologies
announces
preliminary
fiscal
financial
results
toronto
stock
exchange
th
montreal
globe
newswire
theratechnologies
theratechnologies
tsx
th
nasdaq
thtx
biopharmaceutical
company
focused
development
commercialization
innovative
therapies
today
announced
select
preliminary
financial
results
third
quarter
ended
august
third
quarter
fiscal
year
company
expects
consolidated
net
revenues
million
million
compared
million
third
quarter
fiscal
year
revenues
third
quarter
primarily
impacted
pandemic
items
related
transition
egrifta
well
higher
expected
rebates
chargebacks
related
prior
reporting
periods
addition
items
impacting
third
quarter
revenues
changed
pharmaceutical
sales
marketing
paradigm
hospitals
clinics
become
less
accessible
sales
representatives
due
restrictions
implemented
appropriate
actions
address
challenges
different
sales
structure
reallocation
resources
increasing
number
virtual
events
giving
company
opportunities
deliver
messages
healthcare
community
believe
measures
support
efforts
grow
sales
egrifta
said
paul
l√©vesque
president
ceo
theratechnologies
august
company
cash
position
including
cash
bonds
money
market
funds
expected
approximately
million
theratechnologies
theratechnologies
tsx
th
nasdaq
thtx
biopharmaceutical
company
focused
development
commercialization
innovative
therapies
addressing
unmet
medical
needs
information
theratechnologies
available
company
website
sedar
edgar
information
press
release
contains
statements
information
collectively
statements
within
meaning
applicable
securities
laws
based
management
beliefs
assumptions
information
currently
available
management
identify
statements
terms
may
could
would
outlook
believe
plan
envisage
anticipate
expect
estimate
negatives
terms
variations
statements
contained
press
release
include
limited
statements
regarding
expected
revenues
cash
position
well
sales
growth
egrifta
statements
based
upon
number
assumptions
include
limited
following
actual
reported
revenues
cash
position
different
reported
herein
ii
unexpected
items
recorded
effect
reducing
increasing
expected
amount
revenues
cash
position
iii
unfavorable
side
effects
discovered
use
products
iv
products
subject
recall
v
business
plan
change
statements
subject
variety
risks
uncertainties
many
beyond
control
could
cause
actual
results
differ
materially
disclosed
implied
statements
contained
press
release
risks
uncertainties
include
among
others
risk
pandemic
adversely
impact
sales
efforts
growth
revenues
b
capacity
suppliers
meet
obligations
us
c
research
development
activities
health
employees
capacity
rely
resources
e
global
trades
ii
ii
unfavorable
side
effects
discovered
use
products
iv
products
subject
recall
v
biosimilar
approved
competing
egrifta
vi
involved
type
litigation
vii
business
plan
change
refer
potential
investors
risk
factors
section
annual
information
form
dated
february
available
sedar
edgar
exhibit
report
form
dated
february
theratechnologies
public
filings
additional
risks
regarding
conduct
business
theratechnologies
reader
cautioned
consider
risks
uncertainties
carefully
put
undue
reliance
statements
statements
reflect
current
expectations
regarding
future
events
speak
date
press
release
represent
expectations
date
undertake
obligation
update
revise
information
contained
press
release
whether
result
new
information
future
events
circumstances
otherwise
except
may
required
applicable
law
media
inquiries
denis
boucher
vice
president
communications
corporate
affairs
investor
inquiries
leah
gibson
senior
director
investor
relations
